{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:51Z","timestamp":1793502711646,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10096-019-03590-3","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T03:02:39Z","timestamp":1559876559000},"page":"1787-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Eravacycline, a newly approved fluorocycline"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-2125","authenticated-orcid":false,"given":"Young Ran","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin Elizabeth","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"key":"3590_CR1","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Guti\u00e9rrez-Guti\u00e9rrez B, Machuca I, Pascual A. (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31(2)","DOI":"10.1128\/CMR.00079-17"},{"key":"3590_CR2","unstructured":"Antibiotic\/Antimicrobial Resistance. Centers for Disease Control and Prevention website. \n                    https:\/\/www.cdc.gov\/drugresistance\/index.html\n                    \n                  . Last reviewed August 18, 2017. Last Updated March 29, 2018. Accessed 6 Sept 2018"},{"key":"3590_CR3","unstructured":"Antimicrobial Drug Resistance. World Health Organization website. \n                    http:\/\/www.who.int\/csr\/disease\/OP_AMR_FINAL.pdf\n                    \n                  . Accessed 6 Sept 2018"},{"key":"3590_CR4","unstructured":"Global action plan on antimicrobial resistance. World Health Organization website. \n                    http:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/\n                    \n                  . Accessed 6 Sept 2018"},{"key":"3590_CR5","unstructured":"Generating antibiotic incentives now. Food and Drug Administration website. \n                    https:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/UCM595188.pdf\n                    \n                  . Accessed 6 Sept 2018"},{"key":"3590_CR6","unstructured":"FDA awards fast track status to tetraphase pharmaceuticals for IV and oral formulations of eravacycline [news release]. Tetraphase Pharmaceuticals, Watertown, MA. April 2, 2014. \n                    https:\/\/ir.tphase.com\/news-releases\/news-release-details\/fda-awards-fast-track-status-tetraphase-pharmaceuticals-iv-and\n                    \n                  #. Accessed 6 Sept 2018"},{"issue":"3","key":"3590_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A et al (2017) Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152(3):224\u2013232","journal-title":"JAMA Surg"},{"issue":"2","key":"3590_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/jm201465w","volume":"55","author":"XY Xiao","year":"2012","unstructured":"Xiao XY, Hunt DK, Zhou J et al (2012) Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55(2):597\u2013605","journal-title":"J Med Chem"},{"issue":"11","key":"3590_CR9","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH (2013) Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57(11):5548\u20135558","journal-title":"Antimicrob Agents Chemother"},{"key":"3590_CR10","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2016","unstructured":"CLSI (2016) Performance Standards for Antimicrobial Susceptibility Testing, 26th edn. CLSI Supplement M100S. Clinical and Laboratory Standards Institute, Wayne","edition":"26"},{"key":"3590_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","volume":"52","author":"EC Goldstein","year":"2018","unstructured":"Goldstein EC, Citron DM, Tyrrell KL (2018) In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species. Anaerobe 52:122\u2013124","journal-title":"Anaerobe"},{"issue":"suppl 2","key":"3590_CR12","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(suppl 2):S27\u2013S72","journal-title":"Clin Infect Dis"},{"key":"3590_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H et al (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76:567\u2013588","journal-title":"Drugs"},{"key":"3590_CR14","volume-title":"In vitro activity of fluorocyclines against Legionella pneumophila, poster 178","author":"J Dubois","year":"2010","unstructured":"Dubois J, Dubois M, Martel JF, Grossman T, Sutcliffe J (2010) In vitro activity of fluorocyclines against Legionella pneumophila, poster 178. 50th ICAAC, Boston"},{"issue":"8","key":"3590_CR15","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1128\/AAC.00240-16","volume":"60","author":"AK Thabit","year":"2016","unstructured":"Thabit AK, Monogue ML, Nicolau DP (2016) Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother 60(8):5072\u20135075","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3590_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","volume":"58","author":"KP Connors","year":"2014","unstructured":"Connors KP, Housman ST, Pope JS et al (2014) Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 58(4):2113\u20132118","journal-title":"Antimicrob Agents Chemother"},{"key":"3590_CR17","unstructured":"Leighton A, Zupanets I, Bezugla N, Plamondon L, Macdonald G, Sutcliffe J (2011) Broad spectrum fluorocycline TP-434 has oral bioavailability in humans, poster 1509. 21st ECCMID\/27th ICC, Milan, Italy"},{"issue":"11","key":"3590_CR18","doi-asserted-by":"publisher","first-page":"e01174","DOI":"10.1128\/AAC.01174-18","volume":"62","author":"JV Newman","year":"2018","unstructured":"Newman JV, Zhou J, Izmailyan S, Tsai L (2018) Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother 62(11):e01174\u2013e01118","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3590_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ijantimicag.2018.01.001","volume":"51","author":"AK Thabit","year":"2018","unstructured":"Thabit AK, Monogue ML, Newman JV, Nicolau DP (2018) Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents 51(5):727\u2013732","journal-title":"Int J Antimicrob Agents"},{"key":"3590_CR20","volume-title":"Package insert","author":"Eravacycline","year":"2018","unstructured":"Eravacycline (2018) Package insert. Tetraphase Pharmaceuticals, Watertown"},{"issue":"4","key":"3590_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1128\/AAC.04967-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, O\u2019Brien W, Kerstein KO, Sutcliffe JA (2015) Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother 59(4):2446\u20132449","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3590_CR22","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1128\/AAC.00366-16","volume":"60","author":"ML Monogue","year":"2016","unstructured":"Monogue ML, Thabit AK, Hamada Y, Nicolau DP (2016) Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 60(8):5001\u20135005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3590_CR23","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","volume":"47","author":"KA Rodvold","year":"2003","unstructured":"Rodvold KA, Danziger LH, Gotfried MH (2003) Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 47(8):2450\u20132457","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3590_CR24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G et al (2014) Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58(4):1847\u20131854","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"3590_CR25","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1086\/431676","volume":"41","author":"T Babinchak","year":"2005","unstructured":"Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E (2005) The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl 5):S354\u2013S367","journal-title":"Clin Infect Dis"},{"issue":"21","key":"3590_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.21037\/atm.2017.08.15","volume":"5","author":"PM Honore","year":"2017","unstructured":"Honore PM, Spapen HD (2017) Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited! Ann Transl Med 5(21):425","journal-title":"Ann Transl Med"},{"key":"3590_CR27","doi-asserted-by":"crossref","unstructured":"Solomkin JS, Gardovskis J, Lawrence K et al (2018) IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis","DOI":"10.1093\/cid\/ciy1029"},{"key":"3590_CR28","unstructured":"Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [news release]. Tetraphase Pharmaceuticals, Watertown, MA. September 8, 2015. \n                    http:\/\/ir.tphase.com\/news-releases\/news-release-details\/tetraphase-announces-top-line-results-ignite2-phase-3-clinical\n                    \n                  . Accessed 7 March 2019"},{"key":"3590_CR29","unstructured":"Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (cUTI). Tetraphase Pharmaceuticals, Watertown, MA. February 13, 2018. \n                    http:\/\/ir.tphase.com\/news-releases\/news-release-details\/tetraphase-announces-top-line-results-ignite3-phase-3-clinical\n                    \n                  . Accessed 6 Aug 2018"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03590-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T08:03:42Z","timestamp":1570262622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03590-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3590"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03590-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"17 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}